Senolytic MSC Therapy: Why Clearing Aged Cells First May Unlock Stem Cell Potential

A June 2026 study shows that senolytic preconditioning dramatically improves MSC efficacy by removing the SASP factors that suppress tissue repair. Plus: AAT-MSCs reverse diabetes via immune reprogramming, and a phase III MSC trial for meniscal repair reaches completion.

Lire la suite...

Stem Cell Therapy for Sports Injuries: What Weekend Warriors Need to Know

A 36-month clinical trial showed zero adverse events and 57% pain reduction when stem cells were injected into torn rotator cuffs. Here’s what weekend warriors and recreational athletes need to know about MSC therapy for sports injuries.

Lire la suite...

Intravenous UC-MSCs for Ischemic Stroke: What the MERIT Phase 1 Trial Tells Us

The MERIT phase 1 trial published in Cell Reports Medicine shows that intravenous UC-MSC therapy is safe in subacute ischemic stroke, with early NIHSS improvement signals. Here’s what clinicians need to know.

Lire la suite...

MSC Therapy for Graft-versus-Host Disease: What 15 RCTs and a Biomarker-Guided Trial Tell Us

A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.

Lire la suite...

CRISPR-Edited Mesenchymal Stem Cells: Engineering the Next Generation of Precision Cell Therapies

A New Chapter in Therapeutic Cell Engineering Mesenchymal stem cells — or more precisely, mesenchymal stromal cells — have occupied a unique niche in translational medicine for the better part of two decades. Their capacity for multilineage differentiation, coupled with robust immunomodulatory and trophic properties, has propelled them into hundreds...

Lire la suite...
Top